Related Experiment Videos
Treatment of NIDDM in youth
M Owada1, Y Nitadori, T Kitagawa
1Department of Pediatrics, Nihon University Hospital, Tokyo, Japan.
Clinical Pediatrics
|March 10, 1998
Abstract:
This study presents the characteristics of 20 children (17 female) with NIDDM who required oral hypoglycemic agent (OHA) therapy. A family history of NIDDM was present in 55%. None had islet cell antibodies (ICA) or glutamic acid decarboxylase (GAD) antibodies. Tolbutamide was the drug of choice; glibenclamide was introduced if glycemic control was not obtained after 2 to 3 months of tolbutamide therapy. Seven of the patients eventually required insulin therapy.